{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:21:12Z","timestamp":1783578072909,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.diagmicrobio.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T17:37:19Z","timestamp":1481909839000},"page":"338-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients"],"prefix":"10.1016","volume":"87","author":[{"given":"Kenneth VI","family":"Rolston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall A.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00520-013-2006-1","article-title":"Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume","volume":"22","author":"Avritscher","year":"2014","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0010","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.diagmicrobio.2014.09.002","article-title":"Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease","volume":"80","author":"Barriere","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.010_bb0020","series-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","first-page":"M26-A","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"1999"},{"key":"10.1016\/j.diagmicrobio.2016.12.010_bb0025","series-title":"Performance standards for antimicrobial susceptibility testing. Vol. Twenty-fifth Informational Supplement","first-page":"M100-S25","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0030","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0035","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijantimicag.2009.08.020","article-title":"Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus","volume":"35","author":"Huang","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0045","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients","volume":"30","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0050","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.diagmicrobio.2012.04.003","article-title":"Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill","volume":"73","author":"Lin","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0060","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America For the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0065","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","article-title":"Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center","volume":"17","author":"Mahajan","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0070","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/00365548.2012.669843","article-title":"Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin","volume":"44","author":"Marconescu","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","article-title":"Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance","volume":"32","author":"Montassier","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0085","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-014-0048-4","article-title":"Current microbiology of surgical site infections in patients with cancer: a retrospective review","author":"Rolston","year":"2014","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ja.2014.30","article-title":"In vitro activity of telavancin compared with vancomycin and linezolid against gram-positive organisms isolated from cancer patients","volume":"67","author":"Rolston","year":"2014","journal-title":"J Antibiot"},{"key":"10.1016\/j.diagmicrobio.2016.12.010_bb0100","article-title":"In vitro activity of dalbavancin and five comparator agents against common and uncommon gram-positive organisms isolated from cancer patients","author":"Rolston","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0105","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/cncr.21801","article-title":"Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer","volume":"106","author":"Safdar","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0110","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12094-015-1442-4","article-title":"Management of infection and febrile neutropenia in patients with solid cancer","volume":"18","author":"Virizuela","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2016.12.010_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931630428X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931630428X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T18:53:53Z","timestamp":1536173633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931630428X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S073288931630428X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.12.010","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}